MedImmune

NCT00807794

A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

NCT00806728

Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

NCT00806208

Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

NCT00813618

Study of MEDI 507 in the Treatment of Pediatric Patients

NCT00263783

Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors

NCT00192348

A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants

NCT00224783

Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults

NCT00192465

Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults

NCT00077493

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

NCT00192504

Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection

NCT00123942

Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease

NCT00192296

Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

NCT00105313

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

NCT00111696

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

NCT00116168

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

NCT00126646

BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

NCT00112112

Safety Study to Evaluate FluMist in Immunocompromised Children

NCT00299819

Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)

NCT00345670

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

NCT00974675

A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma

NCT00512486

A Sequential Dose-Escalation Study in Subjects With Mild Asthma

NCT00472758

A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545

NCT00587457

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia

NCT00586924

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

NCT00482989

A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus

NCT00493285

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age

NCT00587015

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)

NCT00538096

A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma

NCT00578682

A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557

NCT00659659

A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma

NCT00638989

A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354

NCT00533091

A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis

NCT00659425

CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

NCT00771420

A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis

NCT00816400

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

NCT00816361

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

NCT00796055

Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors

NCT00930683

A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma

NCT01072591

Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

NCT00946699

A Study of the Safety and Tolerability of MEDI-551 in Scleroderma

NCT01102400

A Study of MEDI-575 in Patients With Advanced Solid Malignancies

NCT01093040

A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects

NCT01093040

A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects

NCT01127321

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

NCT01303705

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

NCT01248949

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

NCT01284231

A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas

NCT01322594

A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease

NCT01352884

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

NCT01957579

A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies

NCT01340040

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

NCT01475305

Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)

NCT01498952

MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

NCT01544348

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

NCT01544361

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

NCT01554800

Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease

NCT01562938

MEDI-557 Adult Dosing

NCT01585766

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

NCT01862900

Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions

NCT01577745

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors

NCT01592396

A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma

NCT01769417

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects

NCT01878123

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis

NCT01913028

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects

NCT02000947

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

NCT01891981

Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

NCT02013804

A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies

NCT01975831

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

NCT02027961

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

NCT02085473

A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers

NCT02088112

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

NCT02114268

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

NCT02115815

A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

NCT02117219

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

NCT02151110

Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

NCT02141542

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

NCT02277574

Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis

NCT02213315

A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects

NCT02255760

Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults

NCT02221960

A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

NCT02261220

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

NCT02262741

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

NCT02274155

Anti-OX40 Antibody in Head and Neck Cancer Patients

NCT02291614

A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer

NCT02289820

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

NCT02290340

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

NCT02350751

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults

NCT02394314

A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers

NCT02318394

A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors

NCT02388347

A Study to Assess the Safety of MEDI7836 in Healthy Adults.

NCT02503774

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

NCT02512900

A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma

NCT02576548

A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.

NCT02524782

A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

NCT02556463

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

NCT02583165

A Study in Adult Subjects With Select Advanced Solid Tumors

NCT02485990

Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)

NCT02669667

Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects

NCT02559024

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

NCT02705482

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

NCT02549651

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

NCT02900157

Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

NCT02780674

A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases

NCT02706405

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT02716805

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

NCT02991911

A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer

NCT03001297

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

NCT03089645

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

NCT03106428

A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

NCT03096795

Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants

NCT03235375

A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects

NCT03347968

Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382

NCT03341013

A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382

NCT03362593

A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses

NCT03385369

A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent

NCT03530397

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

NCT03489525

MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma

NCT03336606

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

NCT03625778

A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants

NCT03654313

Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus

NCT03811652

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

NCT03946800

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

NCT03199040

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

NCT04091373

A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide

NCT03889275

A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors

NCT04208620

Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus

NCT04261075

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

NCT04522323

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma